{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:11:20Z","timestamp":1778220680436,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of Hebei Province, China","award":["H2022206533"],"award-info":[{"award-number":["H2022206533"]}]},{"name":"Natural Science Foundation of Hebei Province, China","award":["H2022206533"],"award-info":[{"award-number":["H2022206533"]}]},{"name":"Natural Science Foundation of Hebei Province, China","award":["H2022206533"],"award-info":[{"award-number":["H2022206533"]}]},{"name":"Natural Science Foundation of Hebei Province, China","award":["H2022206533"],"award-info":[{"award-number":["H2022206533"]}]},{"name":"Natural Science Foundation of Hebei Province, China","award":["H2022206533"],"award-info":[{"award-number":["H2022206533"]}]},{"name":"Natural Science Foundation of Hebei Province, China","award":["H2022206533"],"award-info":[{"award-number":["H2022206533"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Albumin-bound paclitaxel (nab-paclitaxel), as a special targeted preparation of paclitaxel, has the advantages of good curative effect and less side effects in anti-tumor therapy. The existence of the plasma-peritoneal barrier and insufficient blood supply make intravenous drugs hard to reach the peritoneum, while hyperthermic intraperitoneal chemotherapy can solve the difficulty. And compared with systemic medications, HIPEC can also give higher concentrations of chemotherapy drugs in the abdominal cavity, while ensuring lower systemic toxicity. However, at present, there is no relevant report on the clinical study of nab-paclitaxel during intraperitoneal hyperthermic chemotherapy, and its stability under special temperature conditions has not been reported either.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study, We examined three batches of albumin-bound paclitaxel dissolved in saline at different temperatures (25\u2009\u00b0C, 37\u2009\u00b0C, 41\u2009\u00b0C, 42\u2009\u00b0C and 43\u2009\u00b0C) for the changes of human serum albumin content, human serum albumin polymer content, related substance content, in-vitro release rate, paclitaxel binding rate and paclitaxel content at different temperatures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our results demonstrated that the indicators including human serum albumin content, human serum albumin polymer content, in-vitro release rate, paclitaxel binding rate and paclitaxel content were stable to the several temperatures, except that Taxane (0.1%) and other individual impurities in the determination of related substance content fluctuated comparatively widely with the change of temperature. In addition, only Taxane (0.1%) and 7-Epitaxol (1%) were detected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Overall, albumin-bound paclitaxel is relatively stable to different temperatures (25\u2009\u00b0C, 37\u2009\u00b0C, 41\u2009\u00b0C, 42\u2009\u00b0C and 43\u2009\u00b0C). This study will lay a foundation for further studies on the albumin-bound paclitaxel during hyperthermic intraperitoneal chemotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-023-00653-2","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T14:02:47Z","timestamp":1677679367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Jingjing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luya","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jintuo","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"issue":"6","key":"653_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"653_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10120-019-00992-2","volume":"23","author":"L Li","year":"2020","unstructured":"Li L, Chen Y, Shen Z, Zhang X, Sang J, Ding Y, et al. Convolutional neural network for the diagnosis of early gastric cancer based on magnifying narrow band imaging. Gastric Cancer. 2020;23(1):126\u201332.","journal-title":"Gastric Cancer"},{"issue":"6","key":"653_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10120-018-0818-x","volume":"21","author":"JH Lee","year":"2018","unstructured":"Lee JH, Park B, Joo J, Kook MC, Kim YI, Lee JY, et al. Body mass index and mortality in patients with gastric cancer: a large cohort study. Gastric Cancer. 2018;21(6):913\u201324.","journal-title":"Gastric Cancer"},{"issue":"1","key":"653_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1186\/s12885-019-5720-3","volume":"19","author":"H Arai","year":"2019","unstructured":"Arai H, Iwasa S, Boku N, Kawahira M, Yasui H, Masuishi T, et al. Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. BMC Cancer. 2019;19(1):652.","journal-title":"BMC Cancer"},{"issue":"8","key":"653_CR5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.ejso.2019.03.011","volume":"45","author":"Y Hao","year":"2019","unstructured":"Hao Y, Liu Y, Ishibashi H, Wakama S, Nishino E, Yonemura Y. Downstaging of lymph node metastasis after neoadjuvant intraperitoneal and systemic chemotherapy in gastric carcinoma with peritoneal metastasis. Eur J Surg Oncol. 2019;45(8):1493\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"653_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1245\/s10434-020-08739-5","volume":"28","author":"B Badgwell","year":"2021","unstructured":"Badgwell B, Ikoma N, Murphy MB, Wang X, Estrella J, Roy-Chowdhuri S, et al. A phase II trial of Cytoreduction, gastrectomy, and Hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric Cancer and Carcinomatosis or positive cytology. Ann Surg Oncol. 2021;28(1):258\u201364.","journal-title":"Ann Surg Oncol"},{"issue":"27","key":"653_CR7","doi-asserted-by":"publisher","first-page":"e20973","DOI":"10.1097\/MD.0000000000020973","volume":"99","author":"Y Lu","year":"2020","unstructured":"Lu Y, Jin Z, Zheng S, Bai Y, Sun Y. Hyperthermic intraperitoneal chemotherapy combined with systemic chemotherapy for gastric cancer peritoneal carcinomatosis: a protocol for systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2020;99(27):e20973.","journal-title":"Medicine (Baltimore)"},{"issue":"13","key":"653_CR8","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1245\/s10434-020-08968-8","volume":"27","author":"AN Blumenthaler","year":"2020","unstructured":"Blumenthaler AN, Allen CJ, Ikoma N, Blum M, Das P, Minsky BD, et al. Laparoscopic HIPEC for low-volume peritoneal metastasis in gastric and gastroesophageal adenocarcinoma. Ann Surg Oncol. 2020;27(13):5047\u201356.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"653_CR9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00595-020-02180-7","volume":"51","author":"T Kitai","year":"2021","unstructured":"Kitai T. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan. Surg Today. 2021;51(7):1085\u201398.","journal-title":"Surg Today"},{"issue":"1","key":"653_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12957-020-02081-6","volume":"18","author":"AE Asmar","year":"2020","unstructured":"Asmar AE, Bendavides M, Moreau M, Hendlisz A, Deleporte A, Khalife M, et al. Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. World J Surg Oncol. 2020;18(1):311.","journal-title":"World J Surg Oncol"},{"issue":"7","key":"653_CR11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00104-019-0982-5","volume":"90","author":"H Leebmann","year":"2019","unstructured":"Leebmann H, Piso P. Hypertherme intraperitoneale Chemotherapie [Hyperthermic intraperitoneal chemotherapy]. Chirurg. 2019;90(7):593\u2013604 German.","journal-title":"Chirurg"},{"issue":"4","key":"653_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.resinv.2019.12.008","volume":"58","author":"M Tanaka","year":"2020","unstructured":"Tanaka M, Hattori Y, Ishii T, Tohnai R, Itoh S, Kawa Y, et al. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients. Respir Investig. 2020;58(4):269\u201374.","journal-title":"Respir Investig"},{"issue":"2","key":"653_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.tranon.2018.01.022","volume":"11","author":"MS Hassan","year":"2018","unstructured":"Hassan MS, Awasthi N, Li J, Williams F, Schwarz MA, Schwarz RE, et al. Superior therapeutic efficacy of nanoparticle albumin bound paclitaxel over Cremophor-bound paclitaxel in experimental esophageal adenocarcinoma. Transl Oncol. 2018;11(2):426\u201335.","journal-title":"Transl Oncol"},{"issue":"12","key":"653_CR14","doi-asserted-by":"publisher","first-page":"6903","DOI":"10.21873\/anticanres.13910","volume":"39","author":"D Ota","year":"2019","unstructured":"Ota D, Akatsuka S, Nishi T, Kato T, Takeuchi M, Tsuji M, et al. Phase I study of combination therapy with weekly nanoparticle albumin-bound paclitaxel and cyclophosphamide in metastatic breast Cancer patients. Anticancer Res. 2019;39(12):6903\u20137.","journal-title":"Anticancer Res"},{"issue":"10","key":"653_CR15","doi-asserted-by":"publisher","first-page":"17360","DOI":"10.18632\/oncotarget.14477","volume":"8","author":"Y Zong","year":"2017","unstructured":"Zong Y, Wu J, Shen K. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(10):17360\u201372.","journal-title":"Oncotarget."},{"issue":"12","key":"653_CR16","doi-asserted-by":"publisher","first-page":"6911","DOI":"10.21873\/anticanres.13068","volume":"38","author":"S Sato","year":"2018","unstructured":"Sato S, Kunisaki C, Tanaka Y, Sato K, Miyamoto H, Yukawa N, et al. A phase II study of tri-weekly low-dose nab-paclitaxel chemotherapy for patients with advanced gastric Cancer. Anticancer Res. 2018;38(12):6911\u20137.","journal-title":"Anticancer Res"},{"issue":"2","key":"653_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/jjco\/hyy180","volume":"49","author":"T Kashiwada","year":"2019","unstructured":"Kashiwada T, Saito Y, Terasaki Y, Hisakane K, Takeuchi S, Sugano T, et al. Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer. Jpn J Clin Oncol. 2019;49(2):165\u201373.","journal-title":"Jpn J Clin Oncol"},{"issue":"12","key":"653_CR18","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2217\/nnm-2018-0485","volume":"14","author":"F Xie","year":"2019","unstructured":"Xie F, Chen R, Zhang L, Yin Z, Zhu Q, You S, et al. Efficacy of two-weekly nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for breast cancer. Nanomedicine (Lond). 2019;14(12):1595\u2013603.","journal-title":"Nanomedicine (Lond)"},{"issue":"1","key":"653_CR19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41598-019-57380-0","volume":"10","author":"H Lee","year":"2020","unstructured":"Lee H, Park S, Kang JE, Lee HM, Kim SA, Rhie SJ. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: a meta-analysis. Sci Rep. 2020;10(1):530.","journal-title":"Sci Rep"},{"key":"653_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.breast.2020.12.002","volume":"55","author":"J Tsurutani","year":"2021","unstructured":"Tsurutani J, Hara F, Kitada M, Takahashi M, Kikawa Y, Kato H, et al. Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. Breast. 2021;55:63\u20138.","journal-title":"Breast."},{"issue":"1","key":"653_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/21691401.2018.1552595","volume":"47","author":"H Tan","year":"2019","unstructured":"Tan H, Hu J, Liu S. Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis. Artif Cells Nanomed Biotechnol. 2019;47(1):268\u201377.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"2","key":"653_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00280-019-03843-0","volume":"84","author":"Y Kato","year":"2019","unstructured":"Kato Y, Okuma Y, Watanabe K, Yomota M, Kawai S, Hosomi Y, et al. A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2019;84(2):351\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"653_CR23","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/1759-7714.13356","volume":"11","author":"S Wang","year":"2020","unstructured":"Wang S, Liang Q, Chi Y, Zhuo M, An T, Duan J, et al. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. Thorac Cancer. 2020;11(5):1149\u201359.","journal-title":"Thorac Cancer"},{"issue":"1","key":"653_CR24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1186\/s12885-020-07199-0","volume":"20","author":"Z Tian","year":"2020","unstructured":"Tian Z, Zhang F, Li P, Wang J, Yang J, Zhang P, et al. Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma. BMC Cancer. 2020;20(1):698.","journal-title":"BMC Cancer"},{"issue":"7","key":"653_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1517\/14656566.2015.1016912","volume":"16","author":"RM Hoffman","year":"2015","unstructured":"Hoffman RM, Bouvet M. Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer. Expert Opin Pharmacother. 2015;16(7):943\u20137.","journal-title":"Expert Opin Pharmacother"},{"key":"653_CR26","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.2147\/DDDT.S165851","volume":"12","author":"R De Luca","year":"2018","unstructured":"De Luca R, Blasi L, Al\u00f9 M, Gristina V, Cicero G. Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer. Drug Des Devel Ther. 2018;12:1769\u201375.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"653_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/jjco\/hyu205","volume":"45","author":"W Koizumi","year":"2015","unstructured":"Koizumi W, Morita S, Sakata Y. A randomized phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE trial). Jpn J Clin Oncol. 2015;45(3):303\u20136.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"653_CR28","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1186\/s12885-020-07614-6","volume":"20","author":"M Okunaka","year":"2020","unstructured":"Okunaka M, Kotani D, Demachi K, Kawazoe A, Yoshino T, Kawasaki T, et al. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. BMC Cancer. 2020;20(1):1111.","journal-title":"BMC Cancer"},{"issue":"7","key":"653_CR29","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/cas.12419","volume":"105","author":"Y Sasaki","year":"2014","unstructured":"Sasaki Y, Nishina T, Yasui H, Goto M, Muro K, Tsuji A, et al. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci. 2014;105(7):812\u20137.","journal-title":"Cancer Sci"},{"issue":"11","key":"653_CR30","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1111\/cas.13813","volume":"109","author":"MM He","year":"2018","unstructured":"He MM, Wang F, Jin Y, Yuan SQ, Ren C, Luo HY, et al. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer. Cancer Sci. 2018;109(11):3575\u201382.","journal-title":"Cancer Sci"},{"issue":"4","key":"653_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00280-019-03887-2","volume":"84","author":"G Roviello","year":"2019","unstructured":"Roviello G, Conter FU, Mini E, Generali D, Traversini M, Lavacchi D, et al. Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. Cancer Chemother Pharmacol. 2019;84(4):669\u201377.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"653_CR32","doi-asserted-by":"publisher","first-page":"e58037","DOI":"10.1371\/journal.pone.0058037","volume":"8","author":"C Zhang","year":"2013","unstructured":"Zhang C, Awasthi N, Schwarz MA, Hinz S, Schwarz RE. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One. 2013;8(2):e58037.","journal-title":"PLoS One"},{"issue":"3","key":"653_CR33","first-page":"1396","volume":"39","author":"J Xiong","year":"2018","unstructured":"Xiong J, Han S, Ding S, He J, Zhang H. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer. Oncol Rep. 2018;39(3):1396\u2013404.","journal-title":"Oncol Rep"},{"issue":"1","key":"653_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000509396","volume":"99","author":"M Nakamura","year":"2021","unstructured":"Nakamura M, Ojima T, Katsuda M, Hayata K, Kitadani J, Nakamori M, et al. Phase 1 study of combined chemotherapy of nab-paclitaxel, S-1, and Oxaliplatin for gastric Cancer with peritoneal metastasis (NSOX study). Oncology. 2021;99(1):57\u201361.","journal-title":"Oncology."},{"issue":"2","key":"653_CR35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.21873\/anticanres.14033","volume":"40","author":"M Sawasaki","year":"2020","unstructured":"Sawasaki M, Tsubamoto H, Nakamoto Y, Kakuno A, Sonoda T. S-1, Oxaliplatin, nab-paclitaxel and Itraconazole for conversion surgery for advanced or recurrent gastric Cancer. Anticancer Res. 2020;40(2):991\u20137.","journal-title":"Anticancer Res"},{"key":"653_CR36","doi-asserted-by":"publisher","first-page":"783243","DOI":"10.3389\/fimmu.2021.783243","volume":"12","author":"JL Lin","year":"2022","unstructured":"Lin JL, Lin JX, Lin JP, Zheng CH, Li P, Xie JW, et al. Safety and efficacy of Camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of gastric Cancer with serosal invasion. Front Immunol. 2022;12:783243.","journal-title":"Front Immunol"},{"issue":"9","key":"653_CR37","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic oncology group study. J Clin Oncol. 1992;10(9):1485\u201391.","journal-title":"J Clin Oncol"},{"issue":"10","key":"653_CR38","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s12094-019-02065-3","volume":"21","author":"I Manzanedo","year":"2019","unstructured":"Manzanedo I, Pereira F, Serrano \u00c1, P\u00e9rez-Viejo E, Mart\u00ednez-Torres B, Carri\u00f3n L, et al. The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study. Clin Transl Oncol. 2019;21(10):1357\u201363.","journal-title":"Clin Transl Oncol"},{"issue":"10251","key":"653_CR39","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635\u201348.","journal-title":"Lancet."},{"issue":"11","key":"653_CR40","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/ijms21114012","volume":"21","author":"J Machlowska","year":"2020","unstructured":"Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11):4012.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00653-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-023-00653-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00653-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T14:04:01Z","timestamp":1677679441000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-023-00653-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1186\/s40360-023-00653-2","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"assertion":[{"value":"27 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}